Scott Nicholas Gettinger MD

Associate Professor Of Medicine (Medical Oncology)

Specialties & Subspecialties

Cancer Center, Yale: Thoracic Oncology Program

Internal Medicine: Medical Oncology

Education & Training

  • B.S., Trinity College (CT) (1991)
  • M.D., State University of New York At Brooklyn College (1999)
  • Resident, Beth Israel Medical Center, NY , Internal Medicine (1999 - 2002)
  • Fellow, Beth Israel Medical Center, NY , Medical Oncology and Hematology (2002 - 2005)

Patient Care

Accepts New Patients? Yes | Patient Type: Adult | Accepts referrals from patients


Clinical Interests

Lung cancer; mesothelioma; thymoma; head and neck cancer; thyroid cancer; mediastinal and chest wall tumors


Cancers Treated

Chest Wall Tumors, Lung, Mediastinal Tumors, Mesothelioma, Thymomas


Board Certifications

  • Hematology (Internal Medicine), Board Eligible
  • Medical Oncology, Board Certified (2005)

Clinical Trials

ConditionsStudy Title
LungA Multi-arm Phase I Safety Study of Nivolumab in Combination with Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects with Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC)
Bladder, Brain and Nervous System, Breast - Female, Cervix Uteri, Colon, Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Multiple Myeloma, Non-Hodgkin's Lymphoma, Other Female Genital, Other Male Genital, Pancreas, Prostate, Rectum, Soft Tissue, Stomach, and ThyroidA Phase I, Open-label, dose-escalation study of the safety and pharmacokinetics of MPDL3280A administered intravenously as a single agent to patients with locally advanced or metastatic solid tumors or hematologic malignancies
LungA Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects With Advanced Non-Small Cell Lung Cancer
Bladder, Breast - Female, Lung, Pancreas, and StomachA Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors
Colon, Lung, and RectumA PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED WITH BEVACIZUMAB AND/OR CHEMOTHERAPY IN PATIENTS WITH ADVANCED SOLID TUMORS

More Clinical Trials...

Edit Profile